Gladman DD, Rigby WFC, Azevedo VF, et al. Efficacy and safety of tofacitinib, an oral janus kinase inhibitor, in patients with active psoriatic arthritis and an inadequate response to tumour necrosis factor inhibitors: OPAL BEYOND, a randomized, double-blind, placebo-controlled, phase 3 trial. EULAR 2017, OP0202.
Met nieuwe leidraad multimorbiditeit op weg naar toekomstbestendige zorg
okt 2024